ReviewNature medicine2022
The promise of precision medicine in rheumatology.
Review in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Molecular mechanisms and risk factors in rheumatoid arthritis: a comprehensive review.Inflammopharmacology · 2026Pooled it
- Clinical-psychosocial archetypes predict short-term outcomes in inflammatory arthritis: an unsupervised segmentation study.Clinical rheumatology · 2026Observational
- Digital twins to accelerate target identification and drug development for immune-mediated disorders.FEBS open bio · 2026Review
- A generalist precision medication framework using temporal causal inference based on treatment-free physiological profiles.Nature communications · 2026Article
- Decomposing heterogeneity in disease progression speeds and pathways.NPJ digital medicine · 2026Article
- Lichenoid granulomatous stomatitis: a series of 12 cases and a literature review.BMC oral health · 2026Review
- Programmable ROS modulation by nanomedicine for rheumatoid arthritis treatment.Materials today. Bio · 2026Review
- Exploration of Multidimensional Treatment for Ankylosing Spondylitis: From Traditional Medications to Emerging Immune-Targeted Perspectives.International journal of general medicine · 2026Review
- B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
- Advances in Understanding the Mechanisms of Treatment for Gouty Arthritis: A Comprehensive Review.Physiological research · 2025Review
- Individual Cortisol Production in Active Rheumatoid Arthritis Associates with Treatment Responses: A Pilot, Two-Year Study.Mediterranean journal of rheumatology · 2025Article
- Understanding rheumatic disease through continuous cell state analysis.Nature reviews. Rheumatology · 2025Review
- Immunophenotypes of Systemic Lupus Erythematosus-Features of Clinical and Laboratory Disorders.Doklady. Biochemistry and biophysics · 2025Article
- Autoantibodies to joint-related peptides as predictive markers in early rheumatoid arthritis.Rheumatology (Oxford, England) · 2025Article
- Association between a history of mental illness and the risk of systemic autoimmune rheumatic diseases: a nationwide, population-based case-control study.Clinical rheumatology · 2025Article
- Virtual patients inspired by multiomics predict the efficacy of an anti-IFNα mAb in cutaneous lupus.iScience · 2025Article
- Breaking research silos to achieve equitable precision medicine in rheumatology.Nature reviews. Rheumatology · 2025Review
- Targeting Cytokine-Mediated Inflammation in Brain Disorders: Developing New Treatment Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- From advanced imaging to molecular insights: the state of the art in omics for axial spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2025Review
- The role of macrophages in hypertrophic scarring: molecular to therapeutic insights.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Systemic autoimmune rheumatic diseases (SARDs) exhibit extensive heterogeneity in clinical presentation, disease course, and treatment response. Therefore, precision medicine - whereby treatment is tailored according to the underlying pathogenic mechanisms of an individual patient at a specific time - represents the 'holy grail' in SARD clinical care. Current strategies include treat-to-target therapies and autoantibody testing for patient stratification; however, these are far from optimal. Recent innovations in high-throughput 'omic' technologies are now enabling comprehensive profiling at multiple levels, helping to identify subgroups of patients who may taper off potentially toxic medications or better respond to current molecular targeted therapies. Such advances may help to optimize outcomes and identify new pathways for treatment, but there are many challenges along the path towards clinical translation. In this Review, we discuss recent efforts to dissect cellular and molecular heterogeneity across multiple SARDs and future directions for implementing stratification approaches for SARD treatment in the clinic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.